Article
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Journal of translational medicine - 15 Aug 2017
Wang Hui, Barbieri Christopher E, He Jintang, Gao Yuqian, Shi Tujin, Wu Chaochao, Schepmoes Athena A, Fillmore Thomas L, Chae Sung-Suk, Huang Dennis, Mosquera Juan Miguel, Qian Wei-Jun, Smith Richard D, Srivastava Sudhir, Kagan Jacob, Camp David G, Rodland Karin D, Rubin Mark A, Liu Tao
Abstract excerpt
BACKGROUND: Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers. However, it remains unclear if mutant SPOP proteins can be utilized as biomarkers for early detection, diagnosis, prognosis or targeted therapy of prostate cancer. Moreover, the SPOP mutation sites are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.